Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria

BMC Gastroenterology, Jan 2014

Background Recent studies suggest that a combination of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) may have theoretical advantages over TACE alone for treatment of hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the effectiveness and safety of radiofrequency ablation following first-line TACE treatment in the management of HCC beyond the Milan Criteria. Methods Forty-five patients who consecutively underwent RFA following first-line TACE treatment for HCC beyond the Milan criteria were enrolled in this study. RFA was performed within 1–2 months after TACE treatment in patients who had incomplete necrotic tumor nodules. Primary effectiveness, complications, survival rates, and prognostic factors were evaluated retrospectively. Results Complete ablation was achieved in 76.2% of the lesions according to 1-month follow-up computed tomography/magnetic resonance imaging evaluation. The mean follow-up period was 30.9 months (range 3–94 months). There were no major complications after RFA therapy. The median overall survival was 29 months (range 20–38 months), with 1-, 2-, and 3-year survival of 89%, 61%, and 43%, respectively. Multivariate analysis revealed that tumor diameter (P = 0.045, hazard ratio [HR] = 0.228, 95% confidence interval [CI]: 0.054-0.968) and pretreatment serum alpha-fetoprotein level (P = 0.024, HR = 2.239, 95% CI: 1.114-4.500) were independent predictors for long-term survival. Conclusions HCC beyond the Milan criteria can be completely and safely ablated by radiofrequency ablation following first-line TACE treatment with a low rate of complications and favorable survival outcome. Further assessment of the survival benefits of combination treatment for HCCs beyond the Milan Criteria is warranted.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

http://www.biomedcentral.com/content/pdf/1471-230X-14-11.pdf

Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria

BMC Gastroenterology Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria Lan Zhang 0 1 Xin Yin 0 1 Yu-hong Gan 0 1 Bo-heng Zhang 0 1 Ju-bo Zhang 0 1 Yi Chen 0 1 Xiao-ying Xie 0 1 Ning-lin Ge 0 1 Yan-hong Wang 0 1 Sheng-long Ye 0 1 Zheng-gang Ren 0 1 0 Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education , 136 Xue Yuan Road, Shanghai 200032 , China 1 Liver Cancer Institute, Zhongshan Hospital, Fudan University , 136 Xue Yuan Road, Shanghai 20032 , China Background: Recent studies suggest that a combination of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) may have theoretical advantages over TACE alone for treatment of hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the effectiveness and safety of radiofrequency ablation following first-line TACE treatment in the management of HCC beyond the Milan Criteria. Methods: Forty-five patients who consecutively underwent RFA following first-line TACE treatment for HCC beyond the Milan criteria were enrolled in this study. RFA was performed within 1-2 months after TACE treatment in patients who had incomplete necrotic tumor nodules. Primary effectiveness, complications, survival rates, and prognostic factors were evaluated retrospectively. Results: Complete ablation was achieved in 76.2% of the lesions according to 1-month follow-up computed tomography/magnetic resonance imaging evaluation. The mean follow-up period was 30.9 months (range 3-94 months). There were no major complications after RFA therapy. The median overall survival was 29 months (range 20-38 months), with 1-, 2-, and 3-year survival of 89%, 61%, and 43%, respectively. Multivariate analysis revealed that tumor diameter (P = 0.045, hazard ratio [HR] = 0.228, 95% confidence interval [CI]: 0.054-0.968) and pretreatment serum alpha-fetoprotein level (P = 0.024, HR = 2.239, 95% CI: 1.114-4.500) were independent predictors for long-term survival. Conclusions: HCC beyond the Milan criteria can be completely and safely ablated by radiofrequency ablation following first-line TACE treatment with a low rate of complications and favorable survival outcome. Further assessment of the survival benefits of combination treatment for HCCs beyond the Milan Criteria is warranted. Hepatocellular carcinoma; Radiofrequency ablation; Transcatheter arterial chemoembolization; Milan criteria - Background Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related mortality worldwide and the second most common in China [1,2]. Despite increased early diagnosis of HCC as a result of surveillance of high-risk populations, only 30% of patients diagnosed with early stage HCC are candidates for curative therapies such as surgical resection or radiofrequency ablation [3]. Moreover, the prognosis of patients with advanced or unresectable HCC remains unsatisfactory due to a low response rate and short time to progression. According to current treatment guidelines, transcatheter arterial chemoembolization (TACE) has been established as the standard therapy for patients who are not eligible for curative therapies [4,5]. Although the survival benefit of TACE treatment has been proved in two randomized clinical trials [5,6], TACE has a primarily palliative effect and does not achieve complete tumor necrosis therefore tumor relapse after TACE is universal [7]. Additionally, repetitive TACE treatments might damage liver function reserve and decrease survival time. Consequently, new strategies are needed to improve the effectiveness of TACE treatment for HCC patients. Percutaneous radiofrequency ablation (RFA) has been accepted as a curative therapy for small HCC, and can provide better local control of the disease than TACE treatment and a similar long-term survival to surgical resection. Previous studies have shown that RFA can achieve complete necrosis in more than 90% of small HCCs [8-10]. Nevertheless, the effectiveness of RFA treatment in patients with intermediate or large HCC is unsatisfactory, with a relatively low complete necrosis rate ranging from 29.0% to 70.0% even if overlapping ablation or repeated procedures are used [11-13]. Therefore, conventional RFA treatment was recommended only for patients with small HCCs confined to the Milan criteria [14]. Recent evidence has suggested that TACE combined with RFA may have a synergistic effect on ablation of HCC [15-17]. To date, few studies have investigated combination therapy of radiofrequency ablation following transarterial arterial chemoembolization for patients with unresectable HCC beyond the Milan criteria. The aim of this study was to evaluate the effectiveness and safety of such combination therapy for unresectable HCC. Methods Patient enrollment This survey is a retrospective study in a single center. The TACE or RFA treatment procedures were accord (...truncated)


This is a preview of a remote PDF: http://www.biomedcentral.com/content/pdf/1471-230X-14-11.pdf

Lan Zhang, Xin Yin, Yu-hong Gan, Bo-heng Zhang, Ju-bo Zhang, Yi Chen, Xiao-ying Xie, Ning-lin Ge, Yan-hong Wang, Sheng-long Ye, Zheng-gang Ren. Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria, BMC Gastroenterology, 2014, pp. 11, 14, DOI: 10.1186/1471-230X-14-11